GTCbio, The San Diego Marriott, La Jolla, CA
January 26-27, 2006
7:00 Registration & Breakfast 7:45 Chairperson's Opening Remarks Session I: Recent Deals in Infectious Diseases 8:00 Building on Successes: Merck's Approach to Anti-infective Partnering Sundeep Lal, Ph.D., MBA, Senior Director, External Scientific Affairs, Merck & Co. 8:30 TBD Gilead 9:00 It’s Not About the Target David Pompliano, Vice President, Biology, MMPD CEDD, GlaxoSmithKline 9:30 Refreshment Break 10:00 PANEL: Recent Partnering and Interest in Antibiotics Chair: Dennis Molnar, Executive Director, Corporate Development, Paratek Pharmaceuticals Praveen Tipirneni, Senior Director, Corporate Development, Cubist Pharmaceuticals Sundeep Lal, Ph.D., MBA, Senior Director, External Scientific Affairs, Merck & Co. Yujiro Hata, VP Business Development, Enanta Pharmaceuticals Session II: Antibiotics/Antifungals 10:45 Review of Global Antibiotic/Antifungal Pipelines Praveen Tipirneni, Senior Director, Corporate Development, Cubist Pharmaceuticals 11:15 Anti-Infective Biologics: A 'Humaneered' Anti-Pseudomonas Antibody Mark Alfenito, President, KaloBios Pharmaceuticals 11:45 The Commercialization Story of Factive and Oscient - The Sequel Glenn Tillotson, VP, Scientific & Medical Relations, Oscient Pharmaceuticals 12:15 Pipeline Building in an Era of Market Segmentation Driven by Drug Resistance Kevin Eastwood, Senior Vice President, Business Development, Achillion Pharmaceuticals 12:45 Lunch 1:45 PANEL: Investment Opportunities in the Anti-Infectives Space Chair: Jeff Stein, Partner, San Diego, Sofinnova Ventures Doug Wall, Partner, Venture Advisors John North, President & CEO, Inimex Eckard Weber, M.D., Venture Partner, Domain Associates Camille Samuels, Managing Director, Versant Ventures Jeanne Cunicelli, Partner, Bay City Capital SESSION III: Valuation and Business Models 2:45 Valuation of Compounds: What does it mean- comparing Anti-Infectives Michael McCully, Director, Recombinant Capital 3:15 The European Biotech Model – Consolidation or Disappointment? Ursula Theuretzbacher, Center for Anti-Infective Agents, Europe 3:45 Refreshment Break SESSION IV: IP and Regulatory 4:15 Developing Pricing & Reimbursement Strategies for Antiinfectives Volker Janssen, Partner, Simon-Kucher & Partners 4:45 Opportunities to Partner w/ the Division of Microbiology & Infectious Diseases Resources Katherine Taylor, Therapeutics Development Program Officer, NIAID, NIH 5:15 Update on Patent Law and Its Impact on Life Sciences Inventions Lisa Haile, Ph.D., J.D., Partner, DLA Piper 5:45 Networking Reception/Poster Viewing Day 2: Friday, January 27, 2006 7:15 Registration & Breakfast 8:00 KEYNOTE ADDRESS From a Biotech to a Biopharmaceutical Company: The Replidyne Story Ken Collins, President & CEO, Replydine, Inc. SESSION V: AntiVirals 8:45 Where are the future areas of growth in infectious diseases, 2006? John Lebbos, M.D., Infectious Diseases Director, Decision Resources, Inc. 9:15 Development of HCV Anti-Viral Therapies: A Partnering Perspective from InterMune Tom Kassberg, SVP, Business Development & Corporate Strategy, InterMune Pharmaceuticals 9:45 Refreshment Break 10:15 Trends in Prophylactic Vaccines Clement Lewin, Vice President US Govt. Affairs & Strategy, Acambis 10:45 NexBio: Leading the Quest for the Ultimate Influenza Medicine Mang Yu, President & CEO, NexBio, Inc. 11:15 PANEL: Bird Flu Pandemic Mang Yu, President & CEO, NexBio, Inc. Invited: Mark Armitage, Chiron Vaccines Invited: Michel Baijot, GSK Invited: Jonathan Klein-Evans, MedImmune 12:00 Lunch SESSION VI: Diagnostics & Drug Discovery Approaches 1:00 Molecular Diagnostics meet Therapeutics Henrik Stender, VP, Research and Development, AdvanDx 1:20 Building Partnering Value through Targeted Antibiotic Discovery and Development Graham Johnson, Chief Research Officer, Rib-X Pharmaceuticals 1:40 Targeted Anti-Infectives for Treatment of Drug Resistant Infections Elizabeth Posillico, President & CEO, Elusys Therapeutics, Inc. 2:10 Tarmogens: Immunotherapy using Recombinant Saccharomyces Cerivisiae for the Treatment of Chronic Viral Diseases David Apelian, M.D., Ph.D., MBA, Chief Medical Officer, GlobeImmune 2:30 Broad-Spectrum Antiviral Drugs: Why not? Paul Olivo, President & CSO, Apath, LLC 2:50 Refreshment Break 3:10 "It's a Jungle Out There": Successful Discovery of New Anti-Infectives from Plants Victoria Gordon, CEO, EcoBiotics 3:30 The Evolving Vaccine Industry, and the Business of Biodefense Elaine Cheung, Sr Mgr Business Development, VaxGen 3:50 Preventing Expression of Chromosomal Resistance Determinates J. Kevin Judice, PhD, CSO, Achaogen, Inc 4:10 Oral Presentations from Selected Abstracts Submit your abstract before Dec. 26, 2005 to be considered 4:30 Conference Concludes Sponsorships & Exhibition Opportunities Available Call 626-256-6405 for More Details
|
|
Invited Speakers:
|
|
KEYNOTE SPEAKER Ken Collins President & CEO, Replidyne, Inc.Tom Kassberg SVP, Bus Development & Corporate Strategy, Intermune Pharmaceuticals Katherine Taylor, Ph.D. Therapeutics Development Program Officer, Office of Biodefense Research Affairs, DMID, NIAID, NIH Glenn S. Tillotson, Ph.D., FRSM Vice President, Scientific and Medical Relations, Oscient Pharmaceuticals Dennis Molnar Executive Director, Corporate Development, Paratek Pharmaceuticals Sundeep Lal, Ph.D., MBA Senior Director, External Scientific Affairs, Merck & Co. Yujiro Hata VP Business Development, Enanta Pharmaceuticals Kevin Eastwood Vice President, Business Development, Achillion Pharmaceuticals Mang Yu, Ph.D. President & CEO, NexBio, Inc. Victoria Gordon CEO, EcoBiotics Discovery Ltd Elaine Cheung Sr Mgr Business Development, VaxGen, Inc. Eckard Weber, M.D. Venture Partner, Domain Associates Camille Samuels Managing Director, Versant Ventures Jeanne Cunicelli Partner, Bay City Capital Paul D. Olivo, M.D., Ph.D. President & CSO, Apath, LLC John Lebbos, M.D. Infectious Diseases Director, Decision Resources, Inc. Michael McCully Director, Recombinant Captial Lisa Haile, Ph.D., J.D. Partner, DLA Piper Rudnick Gray Cary Mark Afenito, Ph.D. President, Kalobios Volker Janssen, Ph.D. Partner, Simon-Kucher & Partners John North, Ph.D. President & CEO, Inimex Pharmaceuticals Henrik Stender, Ph.D. VP, Research and Development, AdvanDx Praveen Tipirneni Senior Director, Corporate Development, Cubist Pharmaceuticals Kevin Judice, Ph.D. CSO, Achaogen, Inc David Pompliano Vice President & Head of Biology, GlaxoSmithKline David Apelian Chief Scientific Officer, GlobeImmune Elizabeth G. Posillico, PhD Elusys Therapeutics, Inc. Jeff Stein, Ph.D. Life Science Venture Partner, Sofinnova Ventures Clement Lewin VP, US Government Affairs & Strategy, Acambis Douglas Wall Partner & Managing Director, West Coast, Venture Advisors Graham Johnson, Ph.D. Chief Research Officer, Rib-X Pharmaceuticals, Inc.
|
|